Halozyme Therapeutics Inc (HALO)
38.97
+0.26
(+0.67%)
USD |
NASDAQ |
Apr 23, 16:00
38.96
-0.01
(-0.03%)
Pre-Market: 20:00
Halozyme Therapeutics Revenue (TTM): 829.25M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 829.25M |
| September 30, 2023 | 780.71M |
| June 30, 2023 | 773.65M |
| March 31, 2023 | 704.98M |
| December 31, 2022 | 660.12M |
| September 30, 2022 | 580.62M |
| June 30, 2022 | 487.48M |
| March 31, 2022 | 471.57M |
| December 31, 2021 | 443.31M |
| September 30, 2021 | 463.01M |
| June 30, 2021 | 412.50M |
| March 31, 2021 | 331.26M |
| December 31, 2020 | 267.59M |
| September 30, 2020 | 199.56M |
| June 30, 2020 | 180.47M |
| March 31, 2020 | 164.40M |
| December 31, 2019 | 195.99M |
| September 30, 2019 | 202.56M |
| June 30, 2019 | 181.88M |
| March 31, 2019 | 177.94M |
| December 31, 2018 | 151.86M |
| September 30, 2018 | 281.19M |
| June 30, 2018 | 319.37M |
| March 31, 2018 | 317.92M |
| December 31, 2017 | 316.61M |
| Date | Value |
|---|---|
| September 30, 2017 | 166.05M |
| June 30, 2017 | 134.17M |
| March 31, 2017 | 133.76M |
| December 31, 2016 | 146.69M |
| September 30, 2016 | 159.92M |
| June 30, 2016 | 148.84M |
| March 31, 2016 | 158.89M |
| December 31, 2015 | 135.06M |
| September 30, 2015 | 113.21M |
| June 30, 2015 | 107.03M |
| March 31, 2015 | 82.03M |
| December 31, 2014 | 75.33M |
| September 30, 2014 | 57.46M |
| June 30, 2014 | 58.86M |
| March 31, 2014 | 54.93M |
| December 31, 2013 | 54.80M |
| September 30, 2013 | 64.09M |
| June 30, 2013 | 53.42M |
| March 31, 2013 | 46.72M |
| December 31, 2012 | 42.32M |
| September 30, 2012 | 22.94M |
| June 30, 2012 | 40.55M |
| March 31, 2012 | 55.98M |
| December 31, 2011 | 56.09M |
| September 30, 2011 | 57.25M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
164.40M
Minimum
Mar 2020
829.25M
Maximum
Dec 2023
438.47M
Average
443.31M
Median
Dec 2021
Revenue (TTM) Benchmarks
| Johnson & Johnson | 89.66B |
| Globus Medical Inc | 1.568B |
| Denali Therapeutics Inc | -- |
| AIM ImmunoTech Inc | 0.202M |
| Protalix BioTherapeutics Inc | 65.49M |